# Tuning antibody stability and function by rational designs of framework mutations

**Authors:** Joseph C. F. Ng, Alicia Chenoweth, Maria Laura De Sciscio, Melanie Grandits, Anthony Cheung, Tooki Chu, Alexandra McCraw, Jitesh Chauhan, Yi Liu, Dongjun Guo, Semil Patel, Alice Kosmider, Daniela Iancu, Sophia N. Karagiannis, Franca Fraternali

PMC · DOI: 10.1080/19420862.2025.2532117 · mAbs · 2025-07-13

## TL;DR

This paper introduces a new method to improve antibody stability and function by making targeted changes to the framework region, not just the CDR.

## Contribution

The study introduces a computational-experimental workflow to rationally design framework mutations that modulate antibody stability and function.

## Key findings

- Framework mutations can stabilize antibodies without affecting antigen binding.
- Molecular dynamics simulations help identify mutations that impact distal antibody functions.
- The approach expands antibody engineering beyond the CDR to include framework and Fc interactions.

## Abstract

Artificial intelligence and machine learning models have been developed to engineer antibodies for specific recognition of antigens. These approaches, however, often focus on the antibody complementarity-determining region (CDR) whilst ignoring the immunoglobulin framework (FW), which provides structural rigidity and support for the flexible CDR loops. Here we present an integrated computational-experimental workflow, combining static structure analyses, molecular dynamics simulations and in vitro physicochemical and functional assays to generate rational designs of FW mutations for modulating antibody stability and activity. We first showed that recent antibody-specific language models lacked insights in FW mutagenesis, in comparison to approaches that use antibody structure information. Using the widely used breast cancer therapeutic trastuzumab as a use case, we designed stabilizing mutants which were distal to the CDR and preserved the antibody’s functionality to engage its cognate antigen (HER2) and induce antibody-dependent cellular cytotoxicity. Interestingly, guided by local backbone motions predicted using molecular dynamics simulations, we designed a FW mutation on the trastuzumab light chain that retained antigen-binding effects, but lost Fab-mediated and Fc-mediated effector functions. This highlighted the effects of FW on immunological functions engendered in distal areas of the antibody, and the importance of considering attributes other than binding affinity when assessing antibody function. Our approach incorporates interdomain dynamics and distal effects between FW and the Fc domains, expands the scope of antibody engineering beyond the CDR, and underscores the importance of a holistic perspective that considers the entire antibody structure in optimizing antibody stability, developability and function.

## Linked entities

- **Proteins:** ERBB2 (erb-b2 receptor tyrosine kinase 2)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, FANCB (FA complementation group B) [NCBI Gene 2187] {aka FA2, FAAP90, FAAP95, FAB, FACB}
- **Diseases:** breast cancer (MESH:D001943), cytotoxicity (MESH:D064420)
- **Chemicals:** trastuzumab (MESH:D000068878)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12269682/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12269682/full.md

## References

89 references — full list in the complete paper: https://tomesphere.com/paper/PMC12269682/full.md

---
Source: https://tomesphere.com/paper/PMC12269682